What Is Trimethoprim Used to Treat?

Trimethoprim is an antibiotic used most often for urinary tract infections, but its reach extends well beyond the bladder. Combined with sulfamethoxazole (a pairing commonly called co-trimoxazole or TMP-SMX), it treats skin infections, prevents life-threatening pneumonia in immunocompromised patients, and is even prescribed in veterinary medicine. The drug’s versatility comes with a few underappreciated side effects and quirks, some of which can mislead both patients and their doctors.

Urinary Tract Infections Are the Bread and Butter

If you’ve been prescribed trimethoprim, there’s a good chance it was for a urinary tract infection. For straightforward, uncomplicated UTIs in women, a three-day course of trimethoprim alone at 100 mg twice daily works about as well as the combination pill (TMP-SMX), while avoiding the risk of severe skin reactions linked to the sulfonamide component.¹ In many countries, trimethoprim on its own is the standard first-line choice for simple bladder infections, prescribed as a short course that clears most infections quickly.

For people who get recurrent UTIs, trimethoprim also works as a long-term preventive agent. Low-dose prophylaxis taken daily or several times a week can keep infections from coming back. In head-to-head trials against nitrofurantoin, another common preventive antibiotic, trimethoprim performed similarly in patients without underlying urinary tract abnormalities.² One important caveat showed up in a study of children: those with structural urinary tract problems or reflux did better on nitrofurantoin, and children on trimethoprim prophylaxis developed high rates of trimethoprim-resistant bacteria during treatment, with resistance jumping from about 8% before prophylaxis to 76% during it.³ That resistance finding is a recurring theme with this drug.

Why Trimethoprim Is Often Paired with Sulfamethoxazole

Trimethoprim works by blocking an enzyme bacteria need to make folate, a vitamin essential for DNA synthesis. Sulfamethoxazole blocks a different step in the same folate-making pathway. For decades, the standard explanation was that sulfamethoxazole simply starves the bacteria of the raw material trimethoprim’s target needs, making trimethoprim more effective. But research has shown the synergy is actually a two-way street: trimethoprim also potentiates sulfamethoxazole by interfering with a feedback loop that bacteria rely on to produce a key folate precursor.⁴ In other words, each drug makes the other more lethal to the bacterium, which is why the combination is so much more potent than either drug alone.

This mutual potentiation matters clinically because it means TMP-SMX can tackle infections that trimethoprim alone might not handle reliably, including more serious or deep-seated infections and certain organisms with partial resistance to one of the two drugs.

Preventing Pneumocystis Pneumonia in Immunocompromised Patients

One of trimethoprim’s most important roles has nothing to do with UTIs. As part of the TMP-SMX combination, it is the gold standard for preventing Pneumocystis pneumonia (PCP), a fungal lung infection that can be fatal in people with weakened immune systems, especially those living with HIV. In a controlled trial comparing TMP-SMX to aerosolized pentamidine for primary prevention, none of the 142 patients in the TMP-SMX groups developed PCP over a mean follow-up of 264 days, compared with about 11% in the pentamidine group.⁵

TMP-SMX also pulls double duty in these patients by simultaneously protecting against toxoplasmosis, another opportunistic infection. A study comparing thrice-weekly TMP-SMX to an alternative regimen found zero cases of PCP in the TMP-SMX group over a median follow-up of 430 days, versus about 6% in the comparison group.⁶ The trade-off is that side effects requiring patients to stop the drug were considerably more common with TMP-SMX, including rash, fever, and blood-count changes. Tolerability remains the main reason some patients end up on alternative prophylaxis.

Skin and Soft Tissue Infections

TMP-SMX has become a go-to antibiotic for skin infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). Community-acquired MRSA skin abscesses and cellulitis are common, and because MRSA is resistant to many older antibiotics, TMP-SMX fills an important gap. In a large trial comparing TMP-SMX with clindamycin for uncomplicated skin infections, cure rates were essentially the same: about 78% for TMP-SMX and 80% for clindamycin in the overall population, with no meaningful difference between the two.⁷ MRSA was present in the majority of S. aureus isolates in that trial, underscoring why TMP-SMX is so useful in communities where MRSA is common.

One question doctors have explored is whether doubling the dose improves outcomes for MRSA skin infections. A study looking at standard-dose versus high-dose TMP-SMX found virtually identical cure rates (about 73–75%), suggesting that the standard dose is already doing the job and escalating does not add benefit.⁸

Chronic Bacterial Prostatitis

Treating prostate infections is notoriously difficult because most antibiotics cannot penetrate prostate tissue well. Trimethoprim is unusual in that it concentrates in prostatic fluid, making it one of the few drugs with the pharmacokinetic profile needed to reach bacteria hiding in the prostate.⁹ That said, the clinical reality is less encouraging than the pharmacology suggests. Only about one third of men with chronic bacterial prostatitis are actually cured after prolonged TMP-SMX therapy.¹⁰ The problem appears to be that the disease itself changes the chemistry of prostate secretions, making them more alkaline and less hospitable to trimethoprim accumulation. So while trimethoprim can theoretically get into the prostate, the infection it’s trying to treat alters the local environment in a way that undermines the drug’s effectiveness.

The Potassium Problem

One of the most clinically significant side effects of trimethoprim is a rise in blood potassium levels. This happens because trimethoprim blocks sodium channels in the kidney’s distal tubule in almost exactly the same way as the potassium-sparing diuretic amiloride.¹¹ When those channels are blocked, the kidney retains potassium instead of excreting it, and blood potassium climbs.¹²

For a young, otherwise healthy person taking a three-day course for a UTI, this is rarely a concern. The danger multiplies when trimethoprim is prescribed to someone already on medications that raise potassium, such as the common heart-failure drug spironolactone. A large study of older patients found that compared with amoxicillin, a course of TMP-SMX was associated with roughly 12 times the risk of hospitalization for dangerously high potassium levels. The researchers estimated that about 60% of hyperkalemia hospitalizations in older patients on spironolactone who received an antibiotic for a UTI could have been avoided by choosing a different antibiotic.¹³ If you take spironolactone, ACE inhibitors, ARBs, or potassium supplements, make sure whoever prescribes trimethoprim knows about them.

When Blood Counts Drop

Because trimethoprim interferes with folate metabolism, it can, in rare cases, suppress the bone marrow’s ability to make blood cells. The most dramatic version of this is pancytopenia, where red cells, white cells, and platelets all fall. This is uncommon, but case reports document it, and the condition typically resolves once the drug is stopped.¹⁴ People most at risk are those already folate-depleted, whether from poor diet, alcohol use, or other medications that drain folate. For patients on long-term prophylactic doses, periodic blood-count monitoring is standard practice for this reason.

The Creatinine Quirk That Mimics Kidney Damage

Trimethoprim has a peculiar habit of making your kidney function look worse on paper than it actually is. Blood creatinine, the most common lab marker used to estimate how well your kidneys are filtering, rises during trimethoprim therapy. An early study documented an average creatinine increase of about 2 mg/L in patients taking standard TMP-SMX doses, but found that actual filtration measured by a separate tracer (iothalamate clearance) did not change at all.¹⁵ The mechanism is straightforward: trimethoprim competes with creatinine for the kidney’s secretion transporters, so less creatinine gets excreted even though the kidney’s filtering capacity is unchanged.¹⁶

Modeling studies have estimated that at typical doses, trimethoprim bumps creatinine levels up by roughly 25–40%, depending on the dose and frequency.¹⁷ This matters practically because a doctor who orders a creatinine test while you’re taking trimethoprim might see a number that looks worrying and consider changing or stopping other medications, ordering further tests, or even suspecting new kidney disease. If you’re on trimethoprim and your blood work comes back with an elevated creatinine, it’s worth flagging the drug before anyone jumps to conclusions. The bump reverses once the antibiotic is stopped.

Pregnancy and Folate Antagonism

Trimethoprim’s mechanism of action creates a specific concern during early pregnancy. By inhibiting folate metabolism, it can interfere with the very nutrient most critical to fetal neural tube development. A large epidemiological study found that folic acid antagonists, trimethoprim among them, may increase the risk not only of neural tube defects but also of cardiovascular defects, oral clefts, and urinary tract defects when used around the time of conception.¹⁸ Animal research has echoed this concern, with mouse studies showing increased rates of cranial neural tube defects following periconceptional trimethoprim exposure.¹⁹

For this reason, trimethoprim is generally avoided in the first trimester and in women who may become pregnant, especially if folic acid supplementation is not already in place. When a UTI needs to be treated in early pregnancy, doctors typically reach for alternatives like nitrofurantoin or cephalosporins instead.

The Growing Resistance Problem

Resistance to trimethoprim has been climbing steadily around the world, and in some regions it has become serious enough to affect prescribing guidelines. In areas with high resistance rates, guidelines now advise against using TMP-SMX empirically for UTIs, meaning you should not take it as a best guess before culture results come back.²⁰ The typical threshold is a local resistance rate above 20%; once a community’s bacteria exceed that level of resistance, the chances of trimethoprim failing become too high for comfort.

The genetic basis of resistance is well studied. Mobile resistance genes called dfrA genes, which code for alternative enzymes that trimethoprim cannot block, have spread widely on plasmids. Genomic analyses show that most of these genes fall into two large families that arose from independent mobilization events, meaning the problem evolved more than once and then spread through bacterial populations on transferable DNA.²¹ A separate class of intrinsically resistant enzymes (type II dihydrofolate reductases, or DfrBs) are structurally unrelated to the enzymes trimethoprim was designed to target and are not inhibited by the drug at all.²² These DfrBs are largely untracked in routine clinical surveillance, raising questions about how much hidden resistance exists beyond what standard tests detect.

For you as a patient, the practical takeaway is that trimethoprim remains effective in many settings but should ideally be guided by urine culture results whenever possible, particularly if you’ve used it before, live in an area with known resistance, or have had a recent treatment failure.

Veterinary Use

Trimethoprim-sulfamethoxazole is not limited to human medicine. It is commonly used in veterinary practice, particularly for urinary tract infections in dogs. A study of female dogs with uncomplicated bacterial cystitis tested a three-day course of TMP-SMX against a ten-day course of cephalexin and found no significant difference in short-term clinical cure rates, with roughly 85–94% of dogs improving within a few days of starting treatment.²³ Longer-term microbiological cure rates were lower in both groups, echoing the human experience that initial symptom relief does not always mean the bacteria are completely gone. The widespread use of trimethoprim in livestock and companion animals also contributes to the growing reservoir of resistant bacteria, a concern that bridges veterinary and human medicine because resistant organisms can move between animals and people.

Why the Same Drug Shows Up for So Many Different Infections

Trimethoprim’s unusually broad range of uses comes down to a few overlapping properties. It achieves good concentrations in urine, prostatic fluid, and skin tissue. It is orally absorbed and inexpensive. The folate pathway it targets is shared by a wide range of bacteria, and when paired with sulfamethoxazole, the two drugs produce synergy that allows coverage of organisms like Pneumocystis that neither drug handles well alone. It also happens to be one of the few oral antibiotics reliably active against community-acquired MRSA, a pathogen that has become extremely common in outpatient settings.

These advantages are real but conditional. Local resistance rates, the patient’s kidney function, potassium-raising medications, pregnancy status, and folate stores all factor into whether trimethoprim is the right choice for a given person. The drug’s long track record and low cost make it irreplaceable in global health, but the steady erosion of its effectiveness through resistance means it cannot be taken for granted. If your doctor suggests trimethoprim, it is still a sound choice in many situations — just not the automatic one it was a generation ago.